MetaCap

Aytu BioPharma (AYTU) vs Serina Therapeutics (SER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed Serina Therapeutics (SER) over the past year, gaining 32.3% versus a loss of 71.9%. Over five years, AYTU leads with a -93.2% price change compared with -95.6% for SER. Serina Therapeutics is the larger company by market cap ($29.8 million vs $28.9 million), about 1.0 times the size.

Aytu BioPharma converts more of its revenue into profit, with a net margin of -24.8% versus -14755.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%SER-71.93%
+50%-14%-78%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%SER-96.03%
+46%-29%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus SER key metrics
MetricAYTUSER
Share price$2.66$1.12
Market cap$28.91M$29.76M
1-day change0.00%-6.67%
YTD return+2.31%-41.45%
1-year return+32.34%-71.93%
5-year return-93.21%-95.64%
Forward P/E17.16—
EPS (TTM)$-1.78$-1.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M$130.00K
Revenue growth (YoY)-13.27%+132.14%
Net income (latest FY)$-14.25M$-19.18M
Gross margin63.95%—
Operating margin-14.44%-18478.46%
Net margin-24.76%-14755.38%
52-week high$3.07$4.26
52-week low$1.75$1.06
Distance from 52-week high-13.36%-73.71%
Analyst consensusstrong_buynone
Avg. price target upside+263.53%+748.21%
Average volume141.18K68.98K
Shares outstanding10.87M26.57M
Employees7516
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed SER by 104.3 percentage points over the past year.
  • Aytu BioPharma is more profitable, keeping -24.8 cents of every revenue dollar as net income versus -14755.4 cents for Serina Therapeutics.
  • Serina Therapeutics grew revenue faster in its latest fiscal year (+132.14% vs -13.27%).

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About Serina Therapeutics

SER stock →

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

AYTU vs SER FAQ

Which is bigger, Aytu BioPharma or Serina Therapeutics?

Serina Therapeutics (SER) is larger, with a market capitalization of $29.76M compared with $28.91M for Aytu BioPharma (AYTU).

Which stock has performed better over the past year, AYTU or SER?

AYTU returned +32.34% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and Serina Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons